Lund Martin, Pedersen Torben B, Feddersen Søren, Østergaard Louise D, Poulsen Charlotte A, Enggaard Christian, Poulsen Mads H A, Lund Lars
Department of Urology, Odense University Hospital, Odense, Denmark.
Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.
Res Rep Urol. 2022 Feb 11;14:33-38. doi: 10.2147/RRU.S346978. eCollection 2022.
Serum levels of the polypeptide chemokine C-C motif ligand 2 (CCL2) have previously shown potential as a prostate cancer diagnostic and prognostic biomarker. Plasma CCL2 levels may be superior to serum levels as a biomarker because of their potentially lower signal-to-noise ratio.
Before initiating a large comparative study of plasma and serum CCL2 levels, we performed a prospective, diagnostic pilot study Of 133 individuals from a clinically relevant population. CCL2 plasma levels were measured using a validated assay kit. Plasma was obtained independently of digital rectal examination.
In this pilot study, we found no relationship between CCL2 plasma values and risk of proven prostate cancer, whereas previous studies found a strong diagnostic relationship between CCL2 serum values and prostate cancer.
Our contribution to the existing literature strengthens the idea that early in the pathological process, CCL2 mainly circulates in large, membrane-enclosed compartments, whereas plasma CCL2 levels increase markedly during disease progression. We conclude that whereas plasma CCL2 levels are not useful as a diagnostic measure, a ratio of CCL2 plasma to serum levels may prove useful as a marker of disease progression, which warrants further study.
此前研究表明，多肽趋化因子C-C基序配体2（CCL2）的血清水平有潜力作为前列腺癌的诊断和预后生物标志物。血浆CCL2水平作为生物标志物可能优于血清水平，因为其信噪比可能更低。
在启动一项关于血浆和血清CCL2水平的大型对比研究之前，我们对133名来自临床相关人群的个体进行了一项前瞻性诊断性初步研究。使用经过验证的检测试剂盒测量CCL2血浆水平。血浆的获取独立于直肠指检。
在这项初步研究中，我们发现CCL2血浆值与确诊前列腺癌风险之间没有关联，而此前的研究发现CCL2血清值与前列腺癌之间存在很强的诊断关联。
我们对现有文献的贡献强化了这样一种观点，即在病理过程早期，CCL2主要在大型膜封闭区室中循环，而血浆CCL2水平在疾病进展过程中会显著升高。我们得出结论，虽然血浆CCL2水平作为诊断指标并无用处，但血浆CCL2与血清水平的比值可能被证明是疾病进展的有用标志物，这值得进一步研究。
